RxDoctor Payments Data

Sureshbhai Patel

Internal Medicine · Leonardtown, MDNPI 1508881020

Payments from drug & device makers

$841in general payments, 2019–2025

Across 33 payments — averaging $25.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$112
  • Exact Sciences$99
  • Ironwood Pharmaceuticals, Inc$86
  • Novo Nordisk$86
  • Amgen$72
  • GSK$64
  • plus $323 from 9 others

What the payments were for

  • Food & beverage$841100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$841 in reported general payments places this provider in the 70th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$450,700
Medicare patients
505
Services billed
13,915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$254,186
OzempicSemaglutide25$48,404
JanuviaSitagliptin Phosphate39$46,616
TradjentaLinagliptin41$39,345
JardianceEmpagliflozin23$35,217
MultaqDronedarone Hcl22$31,664
JanumetSitagliptin Phos/Metformin Hcl26$30,690
XareltoRivaroxaban17$25,289
Spiriva HandihalerTiotropium Bromide23$21,816
Spiriva RespimatTiotropium Bromide36$20,766
LinzessLinaclotide14$19,033
Incruse ElliptaUmeclidinium Bromide23$14,628
Breo ElliptaFluticasone/Vilanterol19$11,478
Combivent RespimatIpratropium/Albuterol Sulfate21$10,332
SymbicortBudesonide/Formoterol Fumarate22$8,981

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Jardiance, Spiriva Respimat, Combivent Respimat$16$105,660121 claims
Novo NordiskOzempic$86$48,40425 claims
Sanofi-aventis U.S. LLCMultaq$46$31,66422 claims
GSKIncruse Ellipta, Breo Ellipta$64$26,10642 claims
AstraZenecaSymbicort$23$8,98122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Leonardtown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →